Cargando…
Targeting the oncogene LSF with either the small molecule inhibitor FQI1 or siRNA causes mitotic delays with unaligned chromosomes, resulting in cell death or senescence
BACKGROUND: The oncogene LSF (encoded by TFCP2) has been proposed as a novel therapeutic target for multiple cancers. LSF overexpression in patient tumors correlates with poor prognosis in particular for both hepatocellular carcinoma and colorectal cancer. The limited treatment outcomes for these di...
Autores principales: | Willoughby, Jennifer L. S., George, Kelly, Roberto, Mark P., Chin, Hang Gyeong, Stoiber, Patrick, Shin, Hyunjin, Pedamallu, Chandra Sekhar, Schaus, Scott E., Fitzgerald, Kevin, Shah, Jagesh, Hansen, Ulla |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296649/ https://www.ncbi.nlm.nih.gov/pubmed/32539694 http://dx.doi.org/10.1186/s12885-020-07039-1 |
Ejemplares similares
-
Transcription factor LSF-DNMT1 complex dissociation by FQI1 leads to aberrant DNA methylation and gene expression
por: Chin, Hang Gyeong, et al.
Publicado: (2016) -
Factor quinolinone inhibitors disrupt spindles and multiple LSF (TFCP2)-protein interactions in mitosis, including with microtubule-associated proteins
por: Yunes, Sarah A., et al.
Publicado: (2022) -
The microtubule-associated histone methyltransferase SET8, facilitated by transcription factor LSF, methylates α-tubulin
por: Chin, Hang Gyeong, et al.
Publicado: (2020) -
FQI1: a transcription-methylation switch for cancer
por: Guryanova, Olga A., et al.
Publicado: (2017) -
Correction for Grant et al., Antiproliferative small-molecule inhibitors of transcription factor LSF reveal oncogene addiction to LSF in hepatocellular carcinoma
Publicado: (2022)